| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.70 | 97.1% |
| Total Income | 0.70 | 97.1% |
| Expenditure | 87.92 | 20.0% |
| PBT | — | |
| Net Profit | -84.83 | 87.7% |
| OPM | — | |
| NPM | — | |
| EPS | -0.99 | 52.3% |
EyePoint Reports Q1 2026 Financial Results
06 May 2026 · 6 May, 4:41 pm
Summary
EyePoint, Inc. announced its financial results for the first quarter ended March 31, 2026. The company reported total net revenue of $0.7 million, a decrease compared to $24.5 million in the same period of 2025, primarily due to the recognition of deferred revenue related to a 2023 agreement. Operating expenses increased to $87.9 million, driven by ongoing DURAVYU Phase 3 clinical trials. The net loss for the quarter was $84.8 million, or ($0.99) per share. The company's cash and investments totaled $223 million as of March 31, 2026, expected to fund operations into Q4 2027.
Key Highlights
- 1
EyePoint reported total net revenue of $0.7 million for the first quarter ended March 31, 2026, compared to $24.5 million for the corresponding period in 2025.
- 2
Operating expenses for the first quarter ended March 31, 2026, totaled $87.9 million, versus $73.3 million in the prior year period.
- 3
The company's net loss was $84.8 million, or ($0.99) per share, compared to a net loss of $45.2 million, or ($0.65) per share, for the corresponding period in 2025.
- 4
As of March 31, 2026, EyePoint had $223 million in cash, cash equivalents, and marketable securities.
- 5
Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026.
- 6
Phase 3 DME clinical trials, COMO and CAPRI, are rapidly advancing with over one-third of patients enrolled; enrollment completion is expected in Q3 2026.
- 7
The company expects its cash, cash equivalents, and marketable securities as of March 31, 2026, will enable it to fund operations into the fourth quarter of 2027.
Management Comments
Jay S. Duker
M.D.
We are entering an important time for EyePoint and the retina community with Phase 3 topline data for DURAVYU in wet AMD expected beginning mid-year with LUGANO topline data and the identical LUCIA trial data readout to follow. In parallel, enrollment in our Phase 3 DME program is meeting our ambitious timelines with full enrollment expected in the third quarter of 2026, positioning DURAVYU for pivotal readouts in the two largest multi-billion-dollar retina markets. DURAVYU is well positioned to potentially bring a new multi-mechanism of action sustained delivery treatment option to patients and physicians in these important retinal disease markets. DURAVYU’s robust clinical profile to date, combined with our de-risked and patient-centric approach, drives our conviction for its best- and first-in-class potential.
Informational and educational content only. Not investment advice.